Dr. Reddys Labs (RDY) Reports Q4 EPS of $0.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dr. Reddy’s Q4 and FY16 Financial Results
May 12, 2016 6:47 AM EDT
Q4 Revenues at Rs. 37.6 billion
(YoY decline of 3%)
Q4 EBITDA at Rs. 4.8 billion
(12.8% of the revenues)
Q4 Adjusted EBITDA* at Rs. 9.0 billion
(24.0% of the
revenues)
FY16 Revenues at Rs. 154.7 billion
(YoY growth of 4%)
FY16 EBITDA at Rs. 36.3 billion
(23.4% of the revenues)
FY16 Adjusted EBITDA* at Rs. 41.2 billion
(26.7% of the
revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE:... More
